BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gao L, Liu Y, Du X, Ma S, Ge M, Tang H, Han C, Zhao X, Liu Y, Shao Y, Wu Z, Zhang L, Meng F, Xiao-Feng Qin F. The intrinsic role and mechanism of tumor expressed-CD38 on lung adenocarcinoma progression. Cell Death Dis 2021;12:680. [PMID: 34226519 DOI: 10.1038/s41419-021-03968-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Deng J, Ke H. Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles. Oncoimmunology 2023;12:2152635. [PMID: 36605619 DOI: 10.1080/2162402X.2022.2152635] [Reference Citation Analysis]
2 Jaina VK, Eedara A, Svs SP, Jadav SS, Chilaka S, Sistla R, Andugulapati SB. Anti-cancer activity of Biochanin A against multiple myeloma by targeting the CD38 and cancer stem-like cells. Process Biochemistry 2022;123:11-26. [DOI: 10.1016/j.procbio.2022.10.029] [Reference Citation Analysis]
3 Gao L, Du X, Li J, Qin FX. Evolving roles of CD38 metabolism in solid tumour microenvironment. Br J Cancer 2022. [PMID: 36396822 DOI: 10.1038/s41416-022-02052-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Astigiano C, Benzi A, Laugieri ME, Piacente F, Sturla L, Guida L, Bruzzone S, De Flora A. Paracrine ADP Ribosyl Cyclase-Mediated Regulation of Biological Processes. Cells 2022;11:2637. [DOI: 10.3390/cells11172637] [Reference Citation Analysis]
5 Xu Q, Liu X, Mohseni G, Hao X, Ren Y, Xu Y, Gao H, Wang Q, Wang Y. Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment. Cancer Cell Int 2022;22:242. [PMID: 35906622 DOI: 10.1186/s12935-022-02664-1] [Reference Citation Analysis]
6 Ma K, Sun L, Shen M, Zhang X, Xiao Z, Wang J, Liu X, Jiang K, Xiao-Feng Qin F, Guo F, Zhang B, Zhang L. Functional assessment of the cell-autonomous role of NADase CD38 in regulating CD8+ T cell exhaustion. iScience 2022;25:104347. [PMID: 35602958 DOI: 10.1016/j.isci.2022.104347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Barrientos-Robledo SG, Cebada-Ruiz JA, Rodríguez-Alba JC, Baltierra-Uribe SL, Díaz Y Orea MA, Romero-Ramírez H. CD38 a biomarker and therapeutic target in non-hematopoietic tumors. Biomark Med 2022. [PMID: 35195042 DOI: 10.2217/bmm-2021-0575] [Reference Citation Analysis]
8 Augustin RC, Leone RD, Naing A, Fong L, Bao R, Luke JJ. Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. J Immunother Cancer 2022;10:e004089. [PMID: 35135866 DOI: 10.1136/jitc-2021-004089] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
9 Lee HC, Deng QW, Zhao YJ. The calcium signaling enzyme CD38 - a paradigm for membrane topology defining distinct protein functions. Cell Calcium 2021;101:102514. [PMID: 34896700 DOI: 10.1016/j.ceca.2021.102514] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
10 Benton TZ, Mills CM, Turner JM, Francis MJ, Solomon DJ, Burger PB, Peterson YK, Dolloff NG, Bachmann AS, Woster PM. Selective targeting of CD38 hydrolase and cyclase activity as an approach to immunostimulation. RSC Adv 2021;11:33260-33270. [DOI: 10.1039/d1ra06266b] [Reference Citation Analysis]